A physician may first learn about a federal prescribing investigation when DEA agents arrive during clinic hours, a pharmacy stops filling prescriptions, or a subpoena demands years of patient charts. What looked like a medical practice the day before can suddenly be described by investigators as a “pill mill.”

That label is powerful, but it is not a criminal charge and it does not decide the case. Federal prosecutors must prove that a licensed professional knowingly or intentionally crossed the line from medical care into unauthorized dispensing.

Keith & Lorfing defends hardworking West Texans when the federal government questions their conduct. If you are under investigation for improper prescribing, healthcare fraud, false claims, kickbacks, or another federal healthcare offense, speak with a healthcare fraud defense lawyer before responding to DEA agents, investigators, auditors, or prosecutors.

What the government means by “pill mill”

“Pill mill” is an investigative label, not a term defined in the Controlled Substances Act. It is commonly used for a clinic, prescriber, or pharmacy suspected of distributing controlled substances without a legitimate medical purpose.

Federal law does not prohibit doctors, nurse practitioners, physician assistants, or pharmacists from handling controlled substances within their authority. A DEA registration authorizes that work, but it does not place a medical professional outside the reach of federal drug laws.

The federal law behind the accusation

21 U.S.C. § 841 generally prohibits the knowing or intentional distribution or dispensing of a controlled substance except as authorized. The same statute can therefore appear in a conventional drug-trafficking case and in a case built around prescriptions.

The authorization question is governed in part by 21 C.F.R. § 1306.04. A controlled-substance prescription must be issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice.

That rule also gives a pharmacist a corresponding responsibility when filling a prescription. A pharmacist who knowingly fills a purported prescription that is not valid may face exposure under federal controlled-substance law.

Bad medicine is not automatically a federal crime

A malpractice dispute asks whether care fell below an objective professional standard. A § 841 prosecution asks a different question: did the defendant know the prescribing or dispensing was unauthorized, or intend to act without authorization?

A poor decision, incomplete chart, or disagreement between experts does not by itself establish criminal intent. Those facts may still be used as circumstantial evidence, but the government has a heavier burden than showing negligence.

Why Ruan v. United States matters

In Ruan v. United States, the Supreme Court rejected a rule that would have allowed conviction based only on an objective view of proper medical practice. Once a defendant produces evidence that the conduct was authorized, the government must prove beyond a reasonable doubt that the defendant knowingly or intentionally acted in an unauthorized manner.

That ruling puts the defendant’s state of mind at the center of a prescribing prosecution. It does not make prescribing records irrelevant, and it does not prevent a jury from inferring intent from the surrounding facts.

What prosecutors may use to argue intent

There is no single checklist that turns a practice into a criminal operation. As in other white-collar investigations, agents usually assemble a pattern from patient files, prescription data, communications, financial records, witness interviews, and the prescriber’s own statements.

Evidence commonly examined includes:

• Patient assessment: whether the record shows a history, examination, diagnosis, and reason for the controlled medication.

• Prescribing patterns: whether many patients received the same drugs, combinations, doses, or early refills without an individualized explanation.

• Monitoring: whether the prescriber checked available prescription history, ordered appropriate testing, and responded to results.

• Warning signs: whether the record addressed suspected diversion, overlapping prescriptions, altered prescriptions, or unsafe combinations.

• Follow-up care: whether the provider tracked function, side effects, treatment goals, referrals, and changes in the patient’s condition.

• Money and communications: whether payment practices, staff messages, marketing, or patient communications support the government’s theory. If investigators also claim that compensation, marketing payments, referral relationships, or other financial arrangements influenced prescribing or patient referrals, the case may overlap with Stark Law and Anti-Kickback Statute allegations.

None of these facts automatically proves guilt. The defense question is what the professional actually knew, why each decision was made, and whether the full record supports a legitimate course of care.

Red flags are the beginning of the inquiry, not the verdict

Prescribing and dispensing patterns can draw attention before an investigator reads a single chart. A provider may stand out because of prescription volume, dosage, patient travel, drug combinations, or differences from peers.

The Texas State Board of Pharmacy instructs pharmacists to consider the total circumstances surrounding possible nontherapeutic dispensing. Its materials identify patterns such as early refills, groups presenting similar prescriptions, long-distance travel, and prescriptions that do not appear to fit the prescriber’s field.

Common areas of scrutiny include:

• Repeated early refills: frequent replacement or refill requests without a documented reason.

• High-risk combinations: opioids prescribed with benzodiazepines, carisoprodol, or other sedating drugs.

• Uniform treatment: nearly identical medication plans for patients with different histories and diagnoses.

• Patient travel: a concentration of patients traveling a considerable distance to one clinic or pharmacy.

• Limited documentation: brief visits or records that do not explain why the medication and dosage were selected.

• Unresolved prescription history: overlapping prescribers, multiple pharmacies, or other information that appears in monitoring data.

• Cash patterns: cash payments or pricing practices that investigators believe do not match ordinary medical operations.

A red flag can have a lawful explanation. Rural access problems, specialist shortages, inherited patient panels, complex chronic conditions, insurance limits, and pharmacy availability can all affect what data looks like when viewed without context.

Texas prescription monitoring requirements

The Texas Prescription Monitoring Program collects dispensing data for Schedule II through V controlled substances. Texas requires certain prescribers and pharmacists to check a patient’s controlled-substance history before prescribing or dispensing opioids, benzodiazepines, barbiturates, or carisoprodol, subject to statutory exceptions.

Failing to document a required check can create licensing and evidentiary problems. It still does not relieve federal prosecutors of their duty to prove the mental state required for a criminal conviction.

Where the evidence in a prescribing case comes from

These cases are often built long before charges are filed. Investigators may compare prescribing data, obtain records by subpoena or search warrant, send undercover patients, interview current or former employees, and ask a medical expert to review selected files.

That means the first defense task is not to give agents an informal explanation. It is to learn the investigation’s scope, preserve records, identify the people and prescriptions at issue, and test the government’s interpretation against the complete medical record.

Records that may matter to the defense

The most useful evidence is often already inside the practice, but it may be spread across different systems. A careful review can include:

• Clinical records: histories, examinations, diagnoses, imaging, prior treatment, medication changes, and documented treatment goals.

• Monitoring records: PMP queries, drug-screen results, pill counts, controlled-substance agreements, and responses to unexpected findings.

• Consultations: specialist referrals, hospital records, prior prescriber information, and communications with pharmacies.

• Electronic data: audit logs, templates, metadata, portal messages, and records showing when an entry was created or changed.

• Practice procedures: written policies, staff training, escalation rules, and responsibility for reviewing incoming information.

• Government data: the method used to select patients, calculate dosages, identify peers, and label a prescription as suspicious.

Records must be preserved as they exist. Changing, adding to, backdating, or deleting a chart after learning of an investigation can create a separate and more serious problem.

Three proceedings may move at the same time

A prescribing investigation can threaten liberty, DEA authority, and a professional license through separate processes. Success or failure in one track does not automatically decide the others.

One response strategy must account for all three. A statement made to address an administrative concern may later be sought or used in a criminal investigation.

Order to show cause

Under 21 U.S.C. § 824, the DEA generally begins a suspension or revocation effort by serving an order to show cause. The order states the legal basis for the proposed action and gives the registrant an opportunity to request a hearing.

An ordinary show-cause order does not itself end the registration. It starts an administrative case in which deadlines, evidence, and the requested hearing require prompt attention.

Immediate suspension

The DEA may issue an immediate suspension when it finds an imminent danger to public health or safety. That action stops the registrant’s controlled-substance authority while the administrative proceeding moves forward.

An immediate suspension is not a criminal conviction, but its practical effect can be severe. The practice may need immediate plans for patient care, controlled-substance inventory, staffing, and communications with pharmacies or facilities.

Voluntary surrender

DEA’s Practitioner’s Manual explains that a registration terminates when a signed DEA Form 104, or other signed writing expressing a desire to surrender, is received by a DEA employee. No further DEA action is required to make that surrender effective.

For that reason, a registrant should not treat Form 104 as routine paperwork. Asking to review the document with independent counsel is not the same as refusing to cooperate; it is a way to understand the immediate professional consequences before making a voluntary decision.

Pharmacists and pharmacies face their own exposure

Federal regulation places primary responsibility for a valid prescription on the prescriber and a corresponding responsibility on the pharmacist who fills it. The regulation specifically refers to a person knowingly filling a purported prescription that was not issued in the usual course of treatment.

The issue is rarely whether a pharmacist noticed one isolated fact. Investigators and pharmacy regulators may ask whether multiple warning signs formed a pattern, what steps were taken to resolve them, and whether the pharmacist documented the decision to dispense or refuse.

Useful evidence may include calls to the prescriber, PMP checks, patient identification, notes about diagnosis or travel, partial fills, refusals, consultation with a pharmacist-in-charge, and pharmacy policies. Texas pharmacy guidance stresses evaluating the total circumstances rather than treating one factor as conclusive.

Penalties depend on the drug, charge, and facts

The draft of an indictment matters. The penalty for a § 841 count depends on the controlled substance, its schedule, any alleged quantity, the applicable subsection, prior qualifying convictions, and whether death or serious bodily injury is alleged.

For many unlawful Schedule II dispensing counts charged under § 841(b)(1)(C), the statutory maximum is 20 years. Other penalty provisions may carry different ranges, so it is not accurate to assign one sentence to every pill mill prosecution.

When death or serious bodily injury is alleged

Certain § 841 penalty provisions impose a 20-year mandatory minimum, with a maximum of life, when death or serious bodily injury results from use of the distributed substance. The enhancement must be charged and proved; it is not automatic because a patient died.

In Burrage v. United States, the Supreme Court held that, unless the drug is independently sufficient to cause the harm, the government must prove it was a but-for cause. In plain language, the government generally must show the death or serious injury would not have happened without the drug at issue.

That question can require a close review of toxicology, autopsy findings, medical history, other substances, timing, tolerance, and expert methods. A drug being present or contributing to death is not necessarily the same as satisfying the statutory causation rule.

Sentencing after a conviction

Federal sentencing is not based only on the maximum written in the statute. The court calculates an advisory guideline range, rules on disputed adjustments, and considers the factors in 18 U.S.C. § 3553(a).

Drug quantity, leadership role, obstruction, acceptance of responsibility, criminal history, and other facts may affect that analysis. The appropriate defense therefore depends on the actual counts and evidence, not a generic estimate.

What to do when the DEA or federal agents make contact

The early goal is to protect accurate records and prevent an unplanned conversation from becoming evidence about intent. A person may assert legal rights without arguing with agents or interfering with their work.

• Identify the request: determine whether agents have a subpoena, inspection notice, search warrant, show-cause order, or request for a voluntary interview.

• Contact independent counsel: the practice’s business lawyer or employer’s lawyer may not represent each individual employee.

• Preserve information: suspend routine destruction and keep charts, messages, billing records, audit logs, and paper files intact.

• Limit informal discussion: do not guess, speculate, or try to explain years of treatment decisions during an unexpected visit.

• Follow lawful process: do not hide records, direct anyone to provide a false account, or obstruct execution of a warrant.

• Review deadlines: subpoenas and administrative orders can require action before criminal charges are filed.

If agents have a warrant, counsel cannot prevent a lawful search. Counsel can still help identify the warrant’s scope, document what was taken, address access to essential patient information, and begin the defense review.

How Keith & Lorfing approaches a pill mill defense

These cases cannot be defended by pointing to a medical license and stopping there. They require a prescription-by-prescription review tied to the government’s evidence of knowledge and intent.

We begin by separating clinical criticism from evidence of a federal crime. Our healthcare fraud defense attorneys examine the prescribing records, billing evidence, compensation arrangements, patient care, government data, and alleged financial incentives before determining whether the case involves a healthcare-fraud theory, controlled-substance charge, or both.That may mean testing the government’s data selection, restoring context to patient files, examining audit logs, working with qualified medical or pharmacy experts, challenging an unreliable causation opinion, and coordinating the criminal response with any DEA or Texas board proceeding.

Our attorneys bring more than 75 years of combined experience and more than 500 jury trials to that work. Russell Lorfing’s experience as a former federal prosecutor also helps us anticipate how the government may organize records, witness testimony, and expert opinions into a theory of intent.

Talk with a West Texas federal defense attorney

A subpoena, DEA visit, search warrant, or show-cause order deserves a response based on the actual document and the actual evidence. Before you surrender a registration, agree to an interview, or try to explain the prescribing record alone, let us help you determine what the government is asking and what is at risk.

Contact Keith & Lorfing or call (325) 480-8100 for a free consultation. 

Frequently asked questions

Is “pill mill” a separate federal offense?

No. It is a label, not the name of a crime in the U.S. Code.

An indictment may instead allege unlawful dispensing under § 841, conspiracy, health care fraud, money laundering, false statements, or other offenses supported by the facts. The government must prove the elements of each charged count.

Does a prescribing guideline violation prove criminal conduct?

No. A guideline, policy, or standard-of-care opinion may be evidence, but it does not replace the mental-state requirement described in Ruan.

The government must prove knowing or intentional unauthorized conduct beyond a reasonable doubt once authorization is properly at issue. The defense should still address departures directly because prosecutors may use them as circumstantial evidence.

Can a pharmacist be prosecuted for filling a prescription?

Yes, but filling a controlled-substance prescription does not automatically create criminal liability. Federal law recognizes a pharmacist’s corresponding responsibility and refers to knowingly filling a purported prescription that is not valid.

The evidence may turn on the warning signs the pharmacist saw, the steps taken to resolve them, the information available at the time, and whether a pattern supports the government’s claim of knowledge or intent.

Will a criminal investigation automatically revoke my license?

No. A federal criminal case, a DEA registration matter, and a Texas licensing proceeding are separate.

The same conduct can trigger all three, and information may move between agencies. A coordinated response is important because resolving one proceeding does not necessarily end the others.

Should I sign DEA Form 104 if agents say the surrender is voluntary?

Do not sign before you understand the effect and receive independent legal advice. According to the DEA’s own manual, a signed surrender terminates the registration when a DEA employee receives it, without further agency action.

Whether surrender is appropriate depends on the individual facts. The decision should be deliberate, not made during an unexpected visit.

What if a patient died after taking a prescribed drug?

A death may prompt close scrutiny, but it does not automatically trigger the enhanced penalty. The government must prove the applicable causation element beyond a reasonable doubt.

The medical record, toxicology, other drugs, underlying conditions, and expert testimony can all matter. Early preservation and independent review of that evidence are important.

How long can a federal prescribing investigation last?

There is no standard length. Investigators may spend months or longer collecting prescription data, records, expert opinions, financial evidence, and witness statements before deciding whether to seek charges.

The absence of an indictment does not mean an investigation has ended. It may create time for counsel to identify the issues, preserve favorable evidence, and prepare for administrative or criminal developments.